Table 7.6g
Immunosuppression Use for Maintenance Between Discharge and One Year Following Transplantation, 1995 to 2004
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	67	113	130	156	220	304	305	375	344	420
Tx with Follow-up Immunosuppression Info	41	71	89	110	168	219	246	271	259	318
Corticosteroids										
Any in Category	87.8%	100.0%	100.0%	100.0%	100.0%	99.1%	98.8%	94.5%	78.8%	73.3%
Steroids	87.8%	100.0%	100.0%	100.0%	100.0%	99.1%	98.8%	94.5%	78.8%	73.3%
Cyclosporine										
Any in Category	68.3%	45.1%	21.3%	32.7%	14.3%	16.0%	15.4%	15.5%	11.2%	7.9%
Cyclosporin	29.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Sandimmmune	9.8%	7.0%	4.5%	5.5%	2.4%	3.2%	0.8%	1.1%	0.0%	0.3%
Neoral	29.3%	38.0%	16.9%	27.3%	11.9%	11.9%	13.0%	12.2%	9.3%	5.0%
Gengraf	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.8%	2.2%	1.5%	2.5%
Eon	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%	0.4%	0.0%
Tacrolimus										
Any in Category	51.2%	67.6%	88.8%	76.4%	91.1%	91.8%	91.9%	87.1%	83.0%	87.7%
Tacrolimus	51.2%	67.6%	88.8%	76.4%	91.1%	91.8%	91.9%	87.1%	83.0%	87.7%
Antimetabolites										
Any in Category	97.6%	100.0%	100.0%	99.1%	95.2%	84.5%	80.5%	80.4%	84.9%	82.1%
Mycophenolate Mofetil	31.7%	83.1%	89.9%	89.1%	86.3%	78.5%	78.0%	78.2%	81.1%	78.9%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%
Azathioprine	65.9%	16.9%	10.1%	10.0%	8.9%	5.9%	2.4%	2.2%	3.5%	0.3%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%
Cytoxan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitors										
Any in Category	0.0%	0.0%	0.0%	0.9%	7.1%	24.7%	30.5%	31.7%	27.8%	25.8%
Sirolimus	0.0%	0.0%	0.0%	0.9%	7.1%	24.7%	30.5%	31.7%	27.8%	25.8%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.